Pakistan ends 'luxury tax' on menstrual products, contraceptives. Will prices drop?

The removal of Pakistan’s 18% sales tax on menstrual products and contraceptives marks a quiet but meaningful shift in public health policy, one that reflects both grassroots activism and the slow unraveling of long-entrenched economic barriers. For years, women’s rights advocates have framed these taxes as not just fiscal measures but as discriminatory practices that disproportionately burden low-income households. The decision arrives after years of protests by feminist groups, who argued that such taxes normalize stigma while making essential hygiene products financially inaccessible for millions of women. In a country where nearly a third of girls miss school during their periods due to lack of supplies, the policy change carries immediate, tangible benefits—potentially lowering prices enough to improve school attendance and workforce participation among women. This move also intersects with broader global trends. In 2021, Kenya became the first African nation to eliminate VAT on sanitary products, and several U.S. states have followed suit in recent years. Pakistan’s reversal suggests a growing recognition that menstrual equity is not a niche issue but a public health necessity. Yet the impact will depend on whether retailers pass the savings to consumers or absorb them as profit. Past tax reductions in Pakistan have seen mixed results, with price drops delayed by supply chain inefficiencies or corporate pricing strategies. The policy’s broader significance lies in its potential to reshape public discourse around gendered economic policies. Contraceptives, similarly taxed, are critical to family planning and maternal health, particularly in a country with one of the highest maternal mortality rates in South Asia. If prices for these products fall, it could ease financial pressures on families while reducing unintended pregnancies—a key factor in poverty alleviation. Still, the victory is partial. The tax exemption does not address quality control issues in menstrual products or the cultural taboos that still discourage open discussion of reproductive health. The real test will be whether this policy sparks further reforms in education and healthcare access. For now, it stands as a rare example of how sustained advocacy can shift entrenched systems—one that future movements may look to as a model.